Vuret adds online evaluations for toenail fungus and hyperhidrosis

Vuret now connects patients with licensed U.S. providers for telehealth evaluations of toenail fungus and hyperhidrosis, with prescriptions filled only by licensed U.S. pharmacies. The platform says every medication requires a valid prescription and is available on a cash-pay basis without insurance billing.

Why it matters: - Vuret is expanding access to telehealth care for two common conditions that can be uncomfortable, persistent and often delayed because patients avoid in-person visits. - The platform’s model keeps diagnosis, prescribing and dispensing inside a licensed care chain. - Patients who want treatment must complete a provider review before any medication can be shipped.

What happened: - Vuret announced that it now offers online evaluations by licensed U.S. healthcare providers for onychomycosis, or toenail fungus, and hyperhidrosis, or excessive sweating. - The telehealth platform is based in the U.S. and operates in Sheridan, Wyoming. - A valid prescription is required for all medication obtained through Vuret. - No medication can be purchased without a prescription.

The details: - Vuret is a platform, not a pharmacy. - Vuret does not sell medication over the counter, make prescribing decisions or prepare and dispense medication. - Patients start by completing an online health questionnaire covering the condition, symptoms and medical history. - A licensed provider reviews the submission and decides whether prescription treatment is medically appropriate. - If treatment is approved, the prescription is sent to a licensed U.S. pharmacy, which prepares and ships the medication to the patient. - If treatment is not appropriate, no prescription is issued and no medication is dispensed. - Onychomycosis is a fungal nail infection that can cause discoloration, thickening and brittleness. - Hyperhidrosis is sweating beyond what the body needs to regulate temperature, and it commonly affects the underarms, hands and feet. - Prescriptions written through the platform are for compounded topical medications. - For onychomycosis, providers may prescribe either an itraconazole-terbinafine topical or an efinaconazole-ciclopirox olamine topical. - For hyperhidrosis, providers may prescribe a topical containing glycopyrrolate. - Compounded medications are prepared by licensed pharmacies to provider specifications and are distinct from FDA-approved branded products. - Compounded medications are not FDA-approved, and the FDA has not evaluated them for safety, effectiveness or quality. - Vuret does not claim compounded medications work better than FDA-approved products. - The provider decides whether a compounded medication is appropriate for an individual patient. - The platform operates on a cash-pay basis and does not bill insurance. - Patients pay directly, and no insurance claim is submitted. - Vuret said insurance plans often do not cover compounded medications, which can lead to denials and appeals. - Vuret said the cash-pay model is simpler because the price shown is the price paid and no claim is filed.

Between the lines: - Vuret is positioning the service around a stricter-than-marketplace workflow, with a real clinical evaluation before any prescription is written. - The platform is also leaning into compounded treatments, which can be useful when standard coverage is limited, but that route comes with added regulatory caution. - The cash-pay approach may reduce friction for some patients while also removing insurance as a payment option.

What's next: - Patients seeking treatment through Vuret will continue through the online questionnaire and provider review process. - If a provider approves care, a licensed U.S. pharmacy will fill the prescription and ship the medication. - If the provider does not approve treatment, the patient will not receive medication through the platform.

The bottom line: - Vuret is betting that a provider-led telehealth model for toenail fungus and hyperhidrosis, paired with cash-pay compounded medications, will appeal to patients who want convenient access without insurance hurdles.